Growth Hormone Secretagogues 101: Sermorelin, Ipamorelin, and CJC-1295 Compared

The shared premise is genuine. Rather than administering recombinant growth hormone directly, a secretagogue prompts the pituitary to release its own, which preserves the feedback architecture of the axis and the pulsatile pattern of secretion. That is a real pharmacological distinction from exogenous rhGH, and it is the strongest argument the category has.

What follows is an appraisal of what is actually known about each compound. It deliberately omits dosing protocols. Two of the three are not lawfully available for human use in most circumstances, and none has been tested in humans for the purposes they are usually prescribed for.

Two different receptors

The first thing to establish is that these compounds do not share a mechanism.

Sermorelin is GHRH(1-29) — the first 29 amino acids of native growth hormone-releasing hormone, which is the biologically active fragment. It binds the GHRH receptor on pituitary somatotrophs and stimulates GH synthesis and release through a Gs-coupled pathway.

CJC-1295 is a modified GHRH(1-29) with four amino acid substitutions that resist enzymatic degradation. Same receptor as sermorelin, engineered for stability.

Ipamorelin is something else entirely. It is a synthetic pentapeptide that binds the growth hormone secretagogue receptor GHS-R1a — the ghrelin receptor — through a Gq-coupled pathway involving phospholipase C and intracellular calcium release. It mimics ghrelin, not GHRH.

This is the reason the compounds are commonly combined. GHRH-receptor and ghrelin-receptor stimulation are separate inputs to the same cell, and engaging both produces a larger GH pulse than either alone. The rationale is sound. What it does not establish is that the resulting GH elevation produces any clinical benefit.

Three different signal patterns

The second axis is duration, and here the differences are extreme.

Sermorelin's half-life is roughly eleven to twelve minutes. It produces a sharp, brief GH pulse and clears before somatostatin feedback fully engages. Ipamorelin's is around two hours, producing one discrete GH episode per administration.

CJC-1295 requires more care, because two distinct compounds are sold under that name.

CJC-1295 with DAC carries a drug affinity complex — a linker that covalently binds circulating albumin after injection, extending plasma half-life to approximately six to eight days.

CJC-1295 without DAC is modified GRF(1-29), often sold as "mod GRF 1-29." It lacks the linker and clears in about thirty minutes.

These are not two strengths of one product. They differ roughly a hundredfold in duration, require entirely different dosing frequencies, and produce fundamentally different patterns of GH exposure. Vendors mislabel them routinely, and a patient who believes they are using a short-acting compound while actually injecting the DAC version is producing continuous rather than pulsatile stimulation.

That distinction connects to the central theoretical claim of the category. The argument for secretagogues over rhGH rests on preserving pulsatility and feedback. A compound engineered to elevate GH and IGF-1 continuously for a week substantially weakens that argument. Sustained IGF-1 elevation with blunted troughs is closer pharmacologically to what exogenous GH does than to physiological secretion, whatever the mechanism of delivery. This tension is rarely acknowledged in material promoting the DAC form.

What the human evidence actually shows

Here the three diverge sharply, and the differences are not what the marketing implies.

Sermorelin has the strongest regulatory history and the weakest modern data. It was approved as Geref for paediatric growth hormone deficiency, initially as a diagnostic agent and subsequently for treatment, and voluntarily withdrawn from the US market by Serono in 2008 for commercial rather than safety reasons — rhGH had captured the indication. [1]

That history means sermorelin was studied to a regulatory standard, in children, for growth hormone deficiency. It does not mean it has been studied in healthy adults for body composition, sleep or recovery, which is what it is now overwhelmingly prescribed for.

Ipamorelin has the most rigorous pharmacological characterisation and a clearly negative clinical record. Developed at Novo Nordisk in the 1990s, it was described in 1998 as the first selective growth hormone secretagogue: it released GH without meaningfully raising ACTH, cortisol or prolactin even at doses two hundred times the GH-releasing threshold. [2]

That selectivity claim is real and well supported. It is also frequently misrepresented. It is a finding about hormonal side effects, largely in animal models — not a finding that ipamorelin releases more GH, and not a finding of clinical benefit.

The clinical programme did not succeed. A phase 2 randomised trial in patients recovering from bowel resection found that intravenous ipamorelin did not beat placebo on its primary endpoint or on any secondary endpoint, and development for that indication was discontinued. [3]

A subsequent dose-finding study completed in 2014 appears never to have published results. Ipamorelin has never been tested in humans for body composition, ageing, sleep or recovery.

CJC-1295 has the thinnest record and the one safety signal worth knowing about. Phase 1 work established dose-dependent GH increases of roughly two to ten fold and IGF-1 increases of one and a half to three fold, sustained for several days after a single dose, with progressive IGF-1 elevation over repeated weekly dosing. [4]

A phase 2 trial in HIV-associated lipodystrophy was halted in 2006 following a cardiovascular death in a participant, which the attending physician attributed to pre-existing coronary disease rather than to the drug. [5]

That attribution may well be correct, and a single event in a trial population with cardiovascular risk factors does not establish causation. But the programme stopped, no sponsor has taken the compound forward in the twenty years since, and there is no registered active development pathway. A clinician should know this before prescribing, and patients researching CJC-1295 online will rarely encounter it.

Regulatory position, as of September 2026

The three occupy different positions, and this is the axis most likely to change.

Sermorelin's prior approval gives it the most defensible compounding basis. Because it was the active ingredient of an FDA-approved drug, it satisfies one of the statutory routes under section 503A, and it was not placed in Category 2. It remains widely compounded under patient-specific prescriptions. Adult use for body composition or ageing is off-label and unapproved.

Ipamorelin and CJC-1295 were both moved into Category 2 in late 2023 and removed from it in April 2026. As covered elsewhere on this site, removal from Category 2 is not authorisation — neither appeared before the July 2026 advisory committee, and neither is currently on the 503A bulks list. A further committee review of additional peptides is anticipated in early 2027. Any clinic advertising these as legal or FDA cleared is misdescribing the position.

Monitoring, if these are used

Whatever one concludes about the evidence, the class effects of stimulating the GH axis are predictable and worth stating.

Baseline and periodic IGF-1 measurement is the minimum, and the target should be the age-adjusted reference range rather than the upper end of it. Glucose and insulin sensitivity warrant attention, since GH is counter-regulatory to insulin. Fluid retention, arthralgia and carpal tunnel symptoms are recognised dose-related effects of GH axis stimulation and typically indicate the dose is too high.

The theoretical concern with sustained IGF-1 elevation and neoplasia is unresolved rather than refuted, and it applies more to continuous-exposure compounds than to short-acting ones. Patients with active malignancy, or a history of it, are not appropriate candidates.

Adult growth hormone deficiency is also a specific diagnosis with defined criteria. Fatigue, poor sleep, unfavourable body composition and reduced exercise tolerance are not diagnostic of it, and treating those symptoms as though they were converts an endocrine intervention into a wellness product.

Where this leaves the three

The honest summary is uncomfortable for the category.

Sermorelin has the best legal footing and a genuine regulatory history, in a population and for an indication unrelated to how it is now used. Ipamorelin has the most careful pharmacology and a clinical programme that failed its endpoints. CJC-1295 has the least human data, an unresolved safety event, no active development, and a formulation ambiguity that creates real risk at the point of purchase.

None of that means the underlying mechanism is wrong. GH axis stimulation does what it says, and the physiology is not in dispute. What is missing is evidence that doing it in healthy or ageing adults improves outcomes that matter, and that gap has persisted for twenty-five years without anyone running the trial that would close it.

For the receptor biology underlying all three, see How peptide hormones signal through receptors. For the current compounding position, see Is peptide therapy legal in your state?.